Recommendations for assessment, monitoring and follow-up of patients with haemophilia

Haemophilia

Volumn 18, Issue 3, 2012, Pages 319-325

  De Moerloose, P ^a   Fischer, K ^b   Lambert, T ^c   Windyga, J ^d   Batorova, A ^e   Lavigne Lissalde, G ^f   Rocino, A ^g   Astermark, J ^h   Hermans, C ⁱ  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c BICÊTRE HOSPITAL   (France)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^f Centre de Traitement des Hémophiles   (France)

^g San Giovanni Bosco Hospital   (Italy)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Follow up; Haemophilia; Laboratory exams; Outcome; Treatment

Indexed keywords

ANALGESIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING TEST; COMORBIDITY; DEMOGRAPHY; DENTAL PROCEDURE; FAMILY HISTORY; FOLLOW UP; HEMARTHROSIS; HEMOPHILIA; HOSPITALIZATION; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; MEDICAL HISTORY; MUSCULOSKELETAL SYSTEM EXAMINATION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SOCIAL PARTICIPATION; STANDARDIZATION; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; JOINT DISEASES; MOTOR ACTIVITY; QUALITY OF LIFE;

EID: 84860323900     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02671.x     Document Type: Review

References (44)

1. Guidelines for the Management of Haemophilia. World Federation of Haemophilia, 2005. Available at
2. Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
3. Swedish Guidelines for: The Care and Treatment of Haemophiliacs. Swedish Haemophilia Society, 2003. Available at
4. Batorova A, Jankovicova D, Zarnovicanova M et al. The national guidelines for the treatment of hemophilia and related inherited bleeding disorders in Slovakia. Lek Obz 2008; 56: 30-40.
5. Windyga J, Chojnowski K, Klukowska A et al. Part I: principles of haemophilia A and B management. Part II: principles of management of haemophilia A and B complicated by inhibitors. Acta Haematol Pol 2008; 39: 537-79.
6. Batlle J, Villar A, Liras A et al. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. Blood Coagul Fibrinolysis 2008; 19: 333-40.
7. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Centre Doctors' organisation (UKHCDO) Guideline Approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
8. Gringeri A, Mannucci PM. Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
9. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors' Organisation. Br J Haematol 2006; 133: 591-605.
10. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12(Suppl. 6): 1-7.
11. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Eng J Med 1993; 328: 453-9.
12. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The recombinate study group. Blood 1994; 83: 2428-35.
13. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83.
14. McMillan CW, Shapiro SS, Whitehurst D et al. The natural history of factor VIII: C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 1988; 71: 344-8.
15. Hermans C, de Moerloose P, Fischer K et al. On behalf of the European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
16. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30(Suppl. 2): 3-6.
17. Feldman BM, Funk SM, Bergstrom BM et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63: 223-30.
18. Soucie JM, Wang C, Forsyth A et al. Range of motion measurements: reference values and a database for comparison studies. Haemophilia 2011; 17: 500-7.
19. Elander J, Robinson G, Mitchell K, Morris J. An assessment of the relative influence of pain coping, negative thoughts about pain, and pain acceptance on health-related quality of life among people with hemophilia. Pain 2009; 145: 169-75.
20. Pettersson H, Nilsson IM, Hedner U, Noréhn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-70.
21. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
22. Doria AS, Babyn PS, Lundin B et al. Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the international prophylaxis study group. Haemophilia 2006; 12: 503-13.
23. Doria AS. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia 2010; 16(Suppl. 5): 107-14.
24. Dolan G. The challenge of an ageing haemophilic population. Haemophilia 2010; 16: 11-6.
25. Van Genderen FR, van Meeteren NL, van der Bom JG et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10: 565-71.
26. Groen WG, van der Net J, Helders PJ, Fischer K. Development and preliminary testing of a paediatric version of the Haemophilia Activities List (pedhal). Haemophilia 2010; 16: 281-9.
27. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia, 2002; 8: 33-43.
28. Steen Carlsson K, Astermark J, Donfield S, Berntorp E. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008; 99: 1060-7.
29. Cardol M, de Haan RJ, van den Bos GA, de Jong BA, de Groot IJ. The development of a handicap assessment questionnaire: the Impact on Participation and Autonomy (IPA). Clin Rehabil 1999; 13: 411-9.
30. Brodin E, Baghaei F, Elfvinger P, Lindvall K, Sunnerhagen KS. The Swedish version of the haemophilia activity list. Haemophilia 2011; 17: 662-8.
31. Dolan P, Lee H, King D, Metcalf R. How does NICE value health? Br Med J 2009; 339: 371-3.
32. Remor E, Young NL, Von Mackensen S, Lopatina EG. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia 2004; 10(Suppl. 4): 30-4.
33. Wasserman J, Aday LA, Begley CE, Ahn C, Lairson DR. Measuring health state preferences for haemophilia: development of disease-specific utility instrument. Haemophilia 2005; 11: 49-57.
34. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF36). Conceptual framework and item selection. Med Care 1992; 30: 473-83.
35. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001; 10: 405-13 discussion 415-20.
36. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378-85.
37. Gandek B, Ware JE, Aaronson NK et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1171-8.
38. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preferences functions. Health utilities index. Pharmacoeconomics 1995; 7: 503-20.
39. Arranz P, Remor E, Quintana M. Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia. Haemophilia 2004; 10: 376-82.
40. Bullinger M, von Mackensen S, Fischer K et al. Pilot testing of the 'Haemo-QoL' quality of life questionnaire for haemophiliac children in six European countries. Haemophilia 2002; 8(Suppl. 2): 47-54.
41. Pollak E, Mühlan H, von Mackensen S, Bullinger M, HAEMO-QOL group. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia 2006; 12: 384-92.
42. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcome-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer 2006; 47: 305-11.
43. Colvin BT, Astermark J, Fischer K et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
44. Astermark J, Negrier C, Hermans C et al. European curriculum for thrombosis and haemostasis. Haemophilia 2009; 15: 337-44.